News | April 04, 2026
BASF Pharma Solutions announces up to 20% price hike on excipients and APIs
The company said the increase—up to 20%—takes effect immediately, or as current contracts allow
The company said the increase—up to 20%—takes effect immediately, or as current contracts allow
The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
Allergan also presented new insights on the growing population of patients on GLP-1 agonists for weight loss who are seeking aesthetic treatments
This strategic acquisition enables CORONA Remedies to penetrate deeper into targeted specialty and offer wider accessibility
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
Subscribe To Our Newsletter & Stay Updated
